9 Meters Biopharma Inc (NMTR)

0.2934
+0.0034(+1.17%)
After Hours
0.2901
-0.0033(-1.1247%)
- Real-time Data
  • Volume:
    2,504,619
  • Day's Range:
    0.2900 - 0.3149
  • 52 wk Range:
    0.1974 - 1.4600
Earnings results expected tomorrow

NMTR Overview

Prev. Close
0.29
Day's Range
0.29-0.3149
Revenue
-
Open
0.302
52 wk Range
0.1974-1.46
EPS
-0.177
Volume
2,504,619
Market Cap
77.68M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
4,297,070
P/E Ratio
-1.50
Beta
0.491
1-Year Change
-72.12%
Shares Outstanding
259,107,380
Next Earnings Date
Aug 17, 2022
What is your sentiment on Innovate Biopharma?
or
Market is currently closed. Voting is open during market hours.

9 Meters Biopharma Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

9 Meters Biopharma Inc Analysis

9 Meters Biopharma Inc Company Profile

9 Meters Biopharma Inc Company Profile

Employees
12

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyNeutralStrong Sell
Technical IndicatorsBuySellStrong BuyStrong BuyStrong Sell
SummaryStrong BuyNeutralStrong BuyBuyStrong Sell
  • what's wrong here??
    0
    • Phase 3 study of larazotide issue, additional number of patients needed to determine clinical outcome is too large to support continued trial. I don't think this means the drug is dead but surely extends entrance to market
      0
  • 9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
    0
    • Insider buying continues. They are still in research mode and incurring losses each quarter - albeit less and less. Promising pipeline. Estimate it will be close to $2 by the end of 2022.
      0
      • Lot of insister buy. Buy and stand
        0
        • Why is this rising? Its good but why?
          0
          • Why this big pressure on this stock???? We are waiting from 2 $
            0
            • No revenue, no profit for few quarters, I would not be hopeful!
              0
            • Cuneyt Comezdon’t you have stock without profit ? Bb
              0
          • insider buying continue
            0
            • Buy buy buy
              0
              • Good time to buy here
                0
                • Phase 2 buy now-->
                  0